Healthcare Industry News:  Mentor Corp 

Biopharmaceuticals Dermatology

 News Release - July 3, 2007

Mentor Announces Initial Patient Injections in Phase III Study for PurTox(R) Botulinum Toxin Type A

SANTA BARBARA, Calif.--(HSMN NewsFeed)--Mentor Corporation (NYSE:MNT ), a leading supplier of medical products for the global aesthetic market, announced today that initial patient enrollment and treatment in its pivotal Phase IIIa study of PurTox® for the reduction of glabellar rhytides (frown lines) by intramuscular injection took place on June 29, 2007. PurTox is a purified botulinum toxin type A neurotoxin. Mentor had previously announced that it received Food and Drug Administration (FDA) approval for its Phase IIIa study protocol and that it anticipated the initiation of this study during its first fiscal quarter.

Joshua H. Levine, President and Chief Executive Officer of Mentor Corporation, commented, "This is a significant step in our long-term growth strategy to expand our presence in facial aesthetic medicine. We believe these Phase III clinical studies will support a successful FDA approval and validate the benefits of a purified toxin."

"We are very excited to be participating in the Phase III studies," said Dr. Corey Maas, Principal Investigator and head of The Maas Clinic in San Francisco. "The early results of the safety and efficacy of PurTox demonstrated in the Phase II study are extremely promising as they relate to aesthetic outcomes for our patients."

In addition, Mentor continues to make substantial progress in its Phase I clinical study for the therapeutic indication of treatment of pain associated with adult onset spasmodic torticollis/cervical dystonia. Multiple cohorts of patients have been treated and follow-up is ongoing.

About Mentor Corporation

Founded in 1969, Mentor Corporation is a leading supplier of medical products for the global aesthetic market. The Company develops, manufactures and markets innovative, science-based products for surgical and non-surgical medical procedures that allow patients to retain a more youthful appearance and improve personal well-being. The Company's website is

Safe Harbor Statement

This press release contains forward-looking statements regarding clinical studies and regulatory activities for Mentor's botulinum toxin type A product. These forward-looking statements are based on our current expectations, estimates and projections about our industry, management's beliefs and certain assumptions made by us. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements speak only as of the date hereof and are based upon the information available to us at this time. Such information is subject to change, and we will not necessarily inform you of such changes. These statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statement as a result of various factors.

The Securities and Exchange Commission filings of Mentor, including, without limitation, its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and recent Current Reports on Form 8-K, discuss important risk factors that could contribute to such differences or otherwise affect its business, results of operations and financial condition. Mentor undertakes no obligation to revise or update publicly any forward-looking statement for any reason.

Source: Mentor Corp

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.